News | May 24, 2025
Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
The company has posted net profit of Rs. 485.62 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.5.71 crores for the Financial Year ended March 31, 2025
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
